Brinks Gilson & Lione
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
Disclosed herein are compounds of formula (I)and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
Cayman Chemical Company, Inc.
C A A A A A A C A A A A A A A A A A A A A A A A A A A C
C07D A61K A61P A61P A61L A61P A61L C07D A61P A61P A61P A61P A61P A61L A61P A61P A61L A61L A61P A61L A61K A61L A61L A61L A61L A61P A61L C07D
inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional
Andriy Bradlee David Adam Kirk M. Fred Lawrence Joseph Michael Stephen Douglas Gregory William James Bernard
Kornilov Germain Uzieblo Maxey Ciske Colombo Barrett Endres Kramer